

Nine Neuroimaging-AI Endophenotypes Unravel Disease Heterogeneity and Partial Overlap across Four Brain Disorders

Junhao Wen^{1,2,3,4,5,6*}, Ye Ella Tian⁷, Zhijian Yang⁸, Yuhan Cui⁸, Guray Erus⁸, Gyujoon Hwang⁸, Erdem Varol⁹, Aleix Boquet-Pujadas¹, Ganesh B. Chand¹⁰, Ilya Nasrallah⁸, Theodore Satterthwaite¹¹, Haochang Shou⁸, Li Shen¹², Arthur W. Toga¹³, Andrew Zalesky⁷, Christos Davatzikos^{8,*}

¹Laboratory of AI and Biomedical Science (LABS), Columbia University, New York, NY, USA

²Department of Radiology, Columbia University, New York, NY, USA

³New York Genome Center (NYGC), New York, NY, USA

⁴Department of Biomedical Engineering, Columbia University, New York, NY, USA

⁵Data Science Institute (DSI), Columbia University, New York, NY, USA

⁶Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID), Department of Radiology, Columbia University, New York, NY, USA

⁷Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia

⁸Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI²D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

⁹Department of Computer Science and Engineering, New York University, New York, USA

¹⁰Department of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA

¹¹Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

¹²Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine, Philadelphia, USA

¹³Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA

*Corresponding authors:

Junhao Wen, junhao.wen89@gmail.com

622 W 168th St, New York, NY 10032

Christos Davatzikos, christos.davatzikos@pennmedicine.upenn.edu

3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States

Word counts: 5669 words

35 **Abstract**

36 Disease heterogeneity poses a significant challenge for precision diagnostics. Recent work
37 leveraging artificial intelligence has offered promise to dissect this heterogeneity by identifying
38 complex intermediate brain phenotypes, herein called dimensional neuroimaging
39 endophenotypes (DNEs). We advance the argument that these DNEs capture the degree of
40 expression of respective neuroanatomical patterns measured, offering a dimensional
41 neuroanatomical representation for studying disease heterogeneity and similarities of neurologic
42 and neuropsychiatric diseases. We investigate the presence of nine such DNEs derived from
43 independent yet harmonized studies on Alzheimer's disease (AD1-2)¹, autism spectrum disorder
44 (ASD1-3)², late-life depression (LLD1-2)³, and schizophrenia (SCZ1-2)⁴, in the general
45 population of 39,178 participants in the UK Biobank study. Phenome-wide associations revealed
46 prominent associations between the nine DNEs and phenotypes related to the brain and other
47 human organ systems. This phenotypic landscape aligns with the SNP-phenotype genome-wide
48 associations, revealing 31 genomic loci associated with the nine DNEs (Bonferroni corrected P-
49 value $< 5 \times 10^{-8}/9$). The DNEs exhibited significant genetic correlations, colocalization, and causal
50 relationships with multiple human organ systems and chronic diseases. A causal effect (odds
51 ratio=1.25 [1.11, 1.40], P-value= 8.72×10^{-4}) was established from AD2, characterized by focal
52 medial temporal lobe atrophy, to AD. The nine DNEs, along with their polygenic risk scores,
53 significantly enhanced the predictive accuracy for 14 systemic disease categories, particularly for
54 conditions related to mental health and the central nervous system, as well as mortality
55 outcomes. These findings underscore the potential of the nine DNEs to capture the expression of
56 disease-related brain phenotypes in individuals of the general population and to relate such
57 measures with genetics, lifestyle factors, and chronic diseases. All results are publicly available
58 at <https://labs-laboratory.com/medicine/>.

59 Main

60 Disease heterogeneity^{2,3,5-10} has been a significant challenge for precision medicine¹¹. A new era
61 powered by artificial intelligence (AI) and large-scale, multi-omics biomarkers may enable us to
62 quantify individualized liability for various brain diseases^{12,13}. Recent work has leveraged semi-
63 supervised clustering methods (**Fig. 1a** and **Supplementary eMethod 1**) to tackle this challenge.
64 These methods characterize disease heterogeneity by constructing a mapping or transformation
65 from a reference group (e.g., healthy controls) to a target group (i.e., patients with a specific
66 disease). In clinical neuroscience, these methods can quantify deviation from typical brain
67 structure measured by T1-weighted magnetic resonance imaging (MRI)^{1,3,2,14}. They represent
68 disease-related neuroanatomical heterogeneity via multiple low-dimensional categorical subtypes
69 associated with specific patterns of brain change relative to the reference group. Instead of
70 focusing on the categorical subtypes, we investigated their corresponding continuous phenotypes
71 (i.e., dimensions)¹⁵, given that many chronic brain diseases develop along a continuous
72 spectrum. Each neuroanatomical pattern's level of expression, therefore, serves as a dimensional
73 AI-derived biomarker pertinent to the respective disease.

74 Previous heterogeneity research has primarily focused on within-disease
75 heterogeneity^{2,3,5-10}. However, this approach neglects the shared disease mechanisms, genetics,
76 and clinical manifestations among different brain diseases. Conversely, while several studies
77 have investigated the shared genetic components across various brain diseases, they have
78 overlooked the important aspect of disease heterogeneity within each condition^{16,17}. As such, a
79 broad perspective is required to investigate disease heterogeneity simultaneously, spanning
80 multiple neurodegenerative and neuropsychiatric disorders. This holistic approach aids in
81 understanding the commonalities and interrelationships between these brain diseases and the
82 multi-organ systems of humans^{18,19}. Such an effort could simultaneously capture neurobiological
83 heterogeneity within disorders and explain shared features, mechanisms, and risk factors across
84 disorders. Ultimately, unraveling neurobiological heterogeneity within neuropsychiatric
85 syndromes and explaining co-morbidity among them promises to accelerate more effective
86 diagnosis, treatment, and prevention strategies.

87 These AI-derived biomarkers capture disease-specific neuroanatomic heterogeneity.
88 However, whether these biomarkers are present in the general population, potentially
89 simultaneously, remains unknown. Here, we sought to measure the presence of multiple AI-
90 based signatures in the general population, delineate common mechanisms among them, and
91 shed light on their relationship with other human organ systems^{20,21}. To do this, we capitalized
92 on nine imaging biomarkers recently derived from regional gray matter (GM) volumetrics
93 derived from several large-scale disease-focused consortia, including ADNI²² for Alzheimer's
94 disease (AD1-2¹), ABIDE²³ for autism spectrum disorder (ASD1-3²), LLD for late-life
95 depression older than 60 years old (LLD1-2³), and PHENOM⁴ for schizophrenia (SCZ1-2⁴).
96 Utilizing semi-supervised clustering and representation learning methodologies²⁴, we obtained
97 nine imaging biomarkers capturing the neuroanatomical diversity across the four distinct brain
98 diseases. AD1 and AD2 illustrate distinct atrophy patterns in the overall brain and medial
99 temporal lobe, respectively¹. ASD1, ASD2, and ASD3 showcase reduced overall volume,
100 expanded subcortical volume, and increased cortical volume². LLD1 and LLD2³ exhibit
101 augmented subcortical volume and overall brain atrophy, respectively. Finally, SCZ1 and SCZ2⁴
102 display global brain atrophy and expanded basal ganglia volume. We first conceptualized these
103 biomarkers as the dimensional neuroimaging endophenotypes (DNE), seeking to test the
104 endophenotype hypothesis in psychiatry²⁵⁻²⁷, which suggests that such measurable intermediate

105 biomarkers (i.e., the endophenotypes) bridge genetics and clinical symptoms and the onset of the
106 disease. They are thought to be more closely related to the underlying etiology and genetics than
107 the complex clinical symptoms or the disease itself. Furthermore, the concept of dimensional
108 representation reinforces the idea that diseases like AD progress along a continuous spectrum. As
109 such, categorizing disease heterogeneity into distinct subtypes overlooks the presence of co-
110 existing patterns within the same individuals (refer to **Method 2a** and **Supplementary eMethod**
111 **1a** for details).

112 We evaluated the manifestation of the nine DNEs in the general population using the
113 neuroimaging and genetic data available in the UK Biobank study²⁸ (UKBB, **Method 1**). The
114 four pre-trained disease-specific AI models (**Method 2**) were applied to the 39,178 UKBB
115 participants with both brain MRI²⁹ and genetic³⁰ data. To delineate the phenotypic landscape of
116 the nine DNEs, we first tested whether the neuroanatomical patterns of the nine DNEs are
117 present in the UKBB general population. Subsequently, we conducted a phenome-wide
118 association study (PWAS, **Method 3**) to establish associations between the nine DNEs and 611
119 UKBB phenotypes, including brain imaging-derived phenotypes (IDPs), traits related to multiple
120 human organ systems, cognition, and lifestyle factors. We performed a genome-wide association
121 study (GWAS, **Method 4**) linking the nine DNEs to 6,477,810 quality-checked common single
122 nucleotide polymorphisms (SNPs) to depict their genetic architecture. Furthermore, we
123 conducted analyses to investigate genetic correlations, colocalization, and causal relationships
124 between the nine DNEs, nine human organ systems¹⁸, and several chronic diseases. Finally, we
125 assessed the ability of the nine DNEs and their corresponding polygenic risk score (PRS) to
126 predict 14 systemic disease categories, 8 cognitive scores, and mortality (**Method 5**).

127

128 **Results**

129 Our analytic framework involves computational genomics, statistical methods, and machine
130 learning to elucidate the phenotypic landscape and genetic architecture of the nine DNEs, as
131 illustrated in **Fig. 1**.

132

133 **All nine DNEs are evident in the general population**

134 We tested whether the neuroanatomical patterns defined in the four disease populations could be
135 found in the general population. We applied the DNE models pre-trained for each disease
136 population to the UKBB general population to measure the degree of expression of each DNE at
137 the individual level. The imaging data from the four disease populations and the UKBB general
138 population were first statistically harmonized via the iSTAGING consortium³² and then linearly
139 corrected in the AI models for common confounders like demographics to alleviate potential
140 domain shifts³³ (**Supplementary eText 1**).

141 We first summarize the neuroanatomical patterns of the nine DNEs (**Fig. 2a** and **Method**
142 **3b**). Overall, the original patterns identified in the disease populations^{1,3,2,14} manifest in the
143 general population. AD1 exhibits a pattern of brain atrophy (i.e., negative correlation) across
144 various brain volumes, while AD2 involves focal atrophy of the medial temporal lobe. ASD1
145 captures a pattern of lower GM volumes in several subcortical regions, including the pallidum,
146 amygdala, and putamen, whereas ASD2 reflects a pattern of relatively larger GM volumes (i.e.,
147 positive correlation) in subcortical regions. ASD3, conversely, is characterized by relatively
148 larger GM volumes in several cortical areas, including the insula. LLD1 (positive correlation)
149 and LLD2 (negative correlation) are characterized by concomitant patterns of regional GM
150 volumes, prominently involving the middle frontal gyrus, the insula, and the thalamus. For
151 schizophrenia, a widespread pattern of reduced brain volumes (e.g., insula) is associated with
152 SCZ1, whereas SCZ2 displays increased volumes of the putamen and pallidum. The details of
153 the P-value, sample sizes, and β values of the linear regression are presented in **Supplementary**
154 **eFile 1** and **2**.

155 The nine DNEs showed different strengths of expression in the general population
156 relative to what is seen in the disease populations from which they were derived. These
157 differences were statistically significant except for ASD2, after correcting for multiple
158 comparisons using the Bonferroni method (**Fig. 2b**). For instance, AD1, characterized by diffuse
159 brain atrophy in the ADNI data, showed a significant under-expression (i.e., a smaller mean of
160 the DNE score) in the general population. Conversely, the subcortical atrophy pattern originally
161 identified in ASD1 from the ABIDE data displayed a significant over-expression (i.e., a larger
162 mean of the DNE score) in the participants from the general population.

163 We then tested whether the nine DNEs differed between the healthy control and disease
164 groups (AD, ASD, LLD, and SCZ; refer to **Method 1** for detailed definitions) in the general
165 UKBB population. Compared to the healthy control group ($N=6390$), a small proportion of
166 patients with the four brain diseases showed significant differences (two-sample t-test) for AD1-
167 2 ($N=23$), LLD1-2 ($N=1329$), and SCZ1-2 ($N=23$), except for ASD1-3 (only 6 ASD patients in
168 this population). For example, AD2, characterized by focal medial temporal lobe atrophy, had a
169 significantly lower mean of DNE in the healthy control (0.29 ± 0.19) compared to the AD patient
170 groups (0.45 ± 0.27 ; $P\text{-value}=1.1\times 10^{-4}$). Detailed statistics for all nine DNEs are presented in
171 **Supplementary eTable 1**.

172 These results proved that the nine DNEs manifest in the general population and convey
173 disease-specific information about the four brain diseases. The contrast in their expression (i.e.,
174 over- and under-expression) between the disease-specific and UKBB general populations is
175 expected and underscores their potential relevance as sub-clinical or vulnerability quantitative
176 indices.

177

178 **The nine DNEs exhibit phenotypic associations with traits beyond the brain**

179 To delineate their phenotypic landscape, we associated the nine DNEs with 611 phenotypes in
180 UKBB. To avoid circularity, the PWAS did not include the 119 GM ROIs derived from T1-
181 weighted MRI, from which the nine DNEs were derived. Out of the 611 additional clinical traits
182 spanning multiple organ systems, cognition, and lifestyle factors, we discovered 1818 significant
183 associations after applying the Bonferroni correction (P -value $< 0.5/611$) (**Fig. 2c**,
184 **Supplementary eFile 3**, and **Method 3c**).

185 Of the 1818 significant associations, 91% were related to the brain. For example, the
186 mean intracellular volume fraction in the superior frontal-occipital fasciculus derived from the
187 multi-shell NODDI³⁴ model was significantly associated with AD1 [$\beta = -0.67 \pm 0.02$, $-\log_{10}(P$ -
188 value) > 300]. Multiple DNEs were significantly associated with the biological age gap (BAG:
189 AI-predicted age minus chronological age) of the brain [e.g., SCZ2: $\beta = 0.19 \pm 0.01$, $-\log_{10}(P$ -
190 value) $= 50.10$]. Furthermore, 2% of the phenotypes related to the musculoskeletal system were
191 associated with the nine DNEs. The nine DNEs were also largely associated with many
192 phenotypes related to mental health (1%). For example, the neuroticism score was significantly
193 associated with LLD2 [$\beta = -1.09 \times 10^{-2} \pm 2.42 \times 10^{-3}$, $-\log_{10}(P$ -value) $= 5.20$] (**Supplementary eFile 3**).
194 A previous study suggests distinct neural mechanisms between older individuals with neurotic
195 and non-neurotic depression, indicating diverse biological pathologies contributing to varying
196 clinical presentations of LLD³⁵.

197 We conducted two sensitivity analyses to validate the main PWAS results. We obtained
198 high concordance rates in split-sample (98.03%) and sex-stratified analyses (93.98%). Detailed
199 results can be found in **Supplementary eText 2** and **Supplementary eFile 4** and **5** for split-
200 sample and sex-stratified analyses.

201 As anticipated, 91% of the significant associations were linked to the brain, given that the
202 DNEs were derived from regional brain volumetrics in brain disease-specific populations.
203 However, it is noteworthy that these phenotypic associations extended beyond the brain,
204 providing evidence for the significant associations between the brain and other organ systems.
205 This brain-body connection was consistent with previous literature on multi-organ research using
206 imaging and genetic data^{18,36,37}.

207 **Genome-wide associations identify 66 genomic loci associated with the nine DNEs**

208 At the genome-wide significance level ($P\text{-value} < 5 \times 10^{-8}$), GWAS using PLINK for a linear
209 regression model (**Method 4a**) identified 10, 8, 5, 21, 9, 1, 3, 3, and 6 genomic loci significantly
210 associated with AD1, AD2, ASD1, ASD2, ASD3, LLD1, LLD2, SCZ1, and SCZ2, respectively
211 (66 in total, **Fig. 3a**, and **Supplementary eFile 6**). At a more stringent significance level ($P\text{-}$
212 $\text{value} < 5 \times 10^{-8}/9$), 31 loci passed the Bonferroni correction, as annotated in **Fig. 3a** (**Method 4c**,
213 query date: 2nd June 2023, via FUMA version: v1.5.4). To support the robustness of our GWAS,
214 we estimated the intercept of linkage disequilibrium score regression (LDSC)³⁸ and obtained
215 intercepts of 0.9997 ± 0.0093 , 1.0325 ± 0.0091 , 0.9962 ± 0.0095 , 1.0172 ± 0.0099 , 1.0117 ± 0.0085 ,
216 1.0135 ± 0.008 , 1.0162 ± 0.0094 , 1.0101 ± 0.0087 , and 1.0124 ± 0.0095 for the nine DNEs. All
217 intercepts were close to 1, indicating no substantial genomic inflation in our GWASs. The
218 Manhattan and QQ plots of the nine GWASs are presented in **Supplementary eFigure 1-9** and
219 are also publicly available on the MEDICINE knowledge portal: [https://labs-](https://labs-laboratory.com/medicine/)
220 [laboratory.com/medicine/](https://labs-laboratory.com/medicine/).

221 All DNEs are significantly heritable ($0.24 < h^2 < 0.66$, $P\text{-value} < 1 \times 10^{-10}$) after Bonferroni
222 correction (**Fig. 3a**, **Supplementary eTable 2**, and **Method 4b**). We employed the GCTA³⁹
223 software to estimate h^2 , acknowledging that previous research has demonstrated variations in the
224 magnitude of h^2 estimates based on the choice of methods. The h^2 estimates obtained through
225 GCTA or similar methods may underestimate SNP-based heritability (i.e., missing heritability),
226 potentially due to unaccounted factors such as gene-environment interactions, epistasis, and rare
227 variant effects.

228 We further investigated the significant genomic loci by mapping them to protein-
229 encoding genes and examining their functional implications through expression quantitative trait
230 loci (eQTL) mapping. **Supplementary eFigure 10** presents the regional Manhattan plot for the
231 most significant genomic locus associated with each DNE. For example, we identified a locus
232 associated with ASD2 (top lead SNP: rs3068507 at 20q11.21) and a neighboring locus associated
233 with SCZ1 (top lead SNP: rs6088962 at 20q11.21), both of which mapped to the *MYLK2* gene
234 (**Supplementary eFigure 10d** and **h**). *MYLK2* encodes a myosin light chain kinase primarily
235 expressed in adult skeletal muscle.

236 We conducted seven sensitivity analyses to validate the main GWAS results (**Method**
237 **4a**). We obtained perfect concordance rates (100%) and similar genomic inflation factors using
238 fastGWA^{40,41} for a generalized linear mixed model in the nine GWAS. Specifically, we excluded
239 the related individuals (up to 2nd-degree) in our genetic quality check pipeline; mixed effect
240 models like fastGWA can detect additional genetic relatedness without excluding individuals by
241 using a sparse genomic relationship matrix, significantly reducing the computational burden for
242 large-scale GWAS. This sensitivity check further supports that no substantial genomic inflation
243 exists in our main GWASs. We also observed high concordance rates in split-sample, sex-
244 stratified (63.26-92.54%), and longitudinal GWAS analyses (100%, $N=1116$), but the
245 concordance rates were relatively low in non-European ancestry GWAS, independent ADNI
246 whole-genome sequencing GWAS, and six case-control GWAS⁴²⁻⁴⁷ of neurodegenerative and
247 neuropsychiatric disorders from the Psychiatric Genomics Consortium (PGC)⁴⁸ (**Supplementary**
248 **eTable 3a**). The sample sizes for the non-European ($N=4783$) and ADNI ($N=1555$) samples are
249 small; the case-control GWAS from the PGC may overlook the heterogeneity within each
250 disease. Detailed results are presented in **Supplementary eText 3** for the sensitivity results,
251 **Supplementary eFile 7-13** for replicated SNPs/loci, and **Supplementary eFigure 1-9** for
252 Manhattan and QQ plots and the LDSC intercepts.

253

254 **The genetic associations of the nine DNEs parallel their phenotypic associations**

255 We performed a phenome-wide look-up analysis (**Method 4d**) to understand the phenotypic
256 associations in the literature for the identified genomic loci in our GWAS.

257 In total, 2525 clinical traits were associated with genetic variants in our GWAS,
258 including traits linked to multiple organ systems, cognition, and lifestyle factors (**Fig. 3b** and
259 **Supplementary eFile 14**). The genomic loci were largely associated with clinical traits of the
260 brain (53%), musculoskeletal (17%), immune system (6%), neurodegenerative (1%), and
261 neuropsychiatric (1%) diseases. For example, AD2 genomic loci were largely associated with
262 traits related to the brain (565 out of 781, e.g., brain IDPs), musculoskeletal (133/781, e.g.,
263 standing height), immune (17/781, e.g., reticulocyte count), cognition (15/781, e.g., cognitive
264 performance), lifestyle factors (13/781, e.g., smoking), and neurodegenerative traits (1/781, i.e.,
265 neurofibrillary tangles).

266 The findings closely align with the phenotypic associations observed in **Fig. 2c**,
267 reinforcing that the DNEs share genetic determinants linked to organs beyond the brain, lifestyle
268 factors, and cognition.

269 **The genetic correlation of the nine DNEs**

270 To understand the shared genetic underpinnings, we estimated the genetic correlation³⁸ (g_c)
271 (**Method 4e**) between the nine DNEs, the BAG of nine human organ systems¹⁸, and six brain
272 diseases (AD, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar,
273 obsessive-compulsive disorder, schizophrenia; **Supplementary eTable 3a**) from PGC and four
274 lifestyle factors and cognitive scores (**Supplementary eTable 3b**).

275 We first estimated the g_c between each pair of DNEs (**Fig. 4a**). Numerous DNEs
276 exhibited strong genetic correlations among each other. The highest positive genetic correlation
277 was obtained between ASD2 and SCZ1 ($g_c=0.57\pm 0.04$); the highest negative genetic correlations
278 were obtained between ASD2 and ASD1 ($g_c=-0.55\pm 0.04$), and between ASD3 and SCZ1 ($g_c=-$
279 0.51 ± 0.05). We also observed a substantial alignment between the phenotypic correlation (p_c)
280 and the genetic correlation of pairwise DNEs, supporting the long-standing Cheverud's
281 Conjecture⁴⁹. However, we identified two exceptions where the observed phenotypic and genetic
282 correlations exhibited opposite directions. ASD1 and ASD3 showed a negative phenotypic ($p_c=-$
283 0.39 ± 0.08) but a positive genetic correlation ($g_c=0.21\pm 0.05$); ASD1 and LLD1 showed a
284 negative phenotypic ($p_c=-0.34\pm 0.09$) but a positive genetic correlation ($g_c=0.16\pm 0.07$)
285 (**Supplementary eTable 4**). This implies that non-genetic factors, such as lifestyle and
286 environmental factors, may exert opposite influences on the two DNEs. We performed additional
287 MAGMA gene-set analysis⁵⁰ to test the genetic similarity between ASD2 and SCZ1. The most
288 significant biological pathway underlying ASD2 is the negative regulation of locomotion (GO
289 0040013, P-value= 2.27×10^{-5} , $\beta=0.22\pm 0.02$), implicated in biological processes that stop, prevent,
290 or reduce the frequency, rate, or extent of locomotion of a cell or organism. The most significant
291 biological pathway for SCZ1 is the negative regulation of neurotransmitter transport (GO
292 0051589, P-value= 1.41×10^{-5} , $\beta=0.22\pm 0.02$), involved in biological processes that downregulate
293 the directed movement of a neurotransmitter into, out of, or within a cell. In particular, the latter
294 supports the involvement of dopamine and glutamate, two major neurotransmitters in the central
295 nervous system, in schizophrenia⁵¹.

296 Between the nine DNEs and the BAGs across nine human organ systems, we found
297 significant genetic correlations between AD1 ($g_c=0.23\pm 0.05$), ASD1 ($g_c=0.44\pm 0.05$), LLD2
298 ($g_c=0.24\pm 0.07$), SCZ1 ($g_c=0.26\pm 0.06$), and the brain BAG, and between ASD1 and the eye BAG
299 ($g_c=0.19\pm 0.07$) (**Fig. 4b** and **Supplementary eTable 5**).

300 Finally, we also found a marginally significant genetic correlation between AD2 and AD
301 ($g_c=0.22\pm 0.12$), AD1 and bipolar disorder (BIP, $g_c=-0.08\pm 0.04$), and ASD3 and BIP
302 ($g_c=0.09\pm 0.04$) using GWAS summary statistics from PGC (**Fig. 4c** and **Supplementary eTable**
303 **6a**). We observed a nominal genetic correlation signal between ASD1 and reaction time
304 ($g_c=0.35\pm 0.15$; **Fig. 4d** and **Supplementary eTable 6b**).

305 In summary, the nine DNEs demonstrate substantial genetic correlations among
306 themselves and with organ systems beyond the brain. These findings highlight the
307 interconnectedness of the neuroanatomical patterns and genetic determinants across multiple
308 body systems and diseases, suggesting shared underlying disease mechanisms and potential
309 pleiotropic effects.

310 **The genetic colocalization of the nine DNEs**

312 To seek the shared causal variants between two clinical traits (e.g., AD1 vs. LLD2), we
313 performed Approximate Bayes Factor colocalization⁵² analyses (**Method 4f**) between the nine
314 DNEs (**Fig. 4e**), with the nine BAGs (**Fig. 4f**), and the six brain disorders from PGC⁴⁸ (**Fig. 4g**).

315 Among the nine DNEs, we detected 44 causal variants (SNPs) exhibiting significant
316 colocalization signals. We showcased the shared causal variant (rs2790099 at 6p21.1) between
317 ASD2 and SCZ2 with a PP.H4.ABF (Approximate Bayes Factor)=0.92 (**Fig. 4e**), which
318 examines the posterior probability (PP) to evaluate the hypothesis, the presence of a single
319 shared causal variant associated with both traits within a specific genomic locus. This causal
320 SNP was mapped to the *RUNX2* gene. The loss of function in *RUNX2* causes a rare autosomal
321 dominant skeletal disorder – cleidocranial dysplasia⁵³, but it was implicated in ASD or SCZ in
322 previous literature.

323 Between the nine DNEs and nine BAGs, we identified 13 causal variants (SNPs)
324 exhibiting significant colocalization signals. We showcased the shared causal variant (rs5848503
325 at 3p22.1) between ASD2 and the brain BAG with a PP.H4.ABF=0.95 (**Fig. 4f**). One mapped
326 gene in this locus is the *MOPB* gene, which encodes the myelin-associated oligodendrocytes
327 basic protein and is actively involved in the structural constituent of the myelin sheath and
328 nervous system development. This gene was previously implicated in ASD using single-cell
329 genomics⁵⁴, SCZ⁵⁵, amyotrophic lateral sclerosis, and Parkinson's disease⁵⁶.

330 Between the nine DNEs and six brain diseases from PGC, we identified 6 causal variants
331 (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant
332 (rs9257566 at 6p22.1) between ASD3 and SCZ with a PP.H4.ABF=0.82 (**Fig. 4g**). In this locus,
333 multiple olfactory receptor (OR) genes and the dysfunction of the olfactory system were
334 implicated in SCZ^{57,58} and ASD^{59,60}. For instance, the *OR2J2* and *OR2J3* genes are two protein-
335 coding genes in copy number variants associated with SCZ using microRNA data⁶¹. The causal
336 SNP (rs9257566) was associated with SCZ and brain IDP, such as white matter microstructural
337 measures (**Supplementary eFigure 11**). Besides those two conditions, AD has also been widely
338 associated with early olfactory dysfunction^{62,63}. The sensitivity checks on the prior probability
339 (p_{12}) for the three illustrations are shown in **Supplementary eFigure 12a-c**. The causal variant,
340 cytogenetic region, and their colocalization signal direction (based on β coefficients) are presented in
341 **Supplementary eFigure 13a-c**. Detailed results are shown in **Supplementary eFile 15-17**.

342 The genetic colocalization of the nine DNEs revealed causal genetic variants, indicating
343 that the same genomic regions may causally influence the expression of these AI-derived
344 endophenotypes.

345

346 **The causal relationship of the nine DNEs**

347 We applied bidirectional two-sample Mendelian randomization analyses⁶⁴ (**Method 4g**) to depict
348 a causal network between the nine DNEs, the eight BAGs (excluding the brain BAG), and eleven
349 chronic diseases spanning the whole-body system.

350 For each pair of DNEs, as the GWAS populations completely overlapped, conducting
351 two-sample Mendelian randomization was not feasible⁶⁵. Alternatively, the split-sample GWAS
352 did not yield sufficient statistical power due to the limited number of instrumental variables (VI)
353 available (< 6 SNPs).

354 Among the nine DNEs and eight BAGs, we found potential causal effects of the eye
355 BAG on LLD1 [P-value=4.57x10⁻³, OR (95% CI) = 1.14 (1.04, 1.24), number of SNPs=16], the
356 cardiovascular BAG on ASD3 [P-value=6.04x10⁻³, OR (95% CI) = 1.16 (1.04, 1.29), number of
357 SNPs=34], and the pulmonary BAG on LLD2 [P-value=1.98x10⁻³, OR (95% CI) = 1.14 (1.04,

358 1.25), number of SNPs=49]. No significant causal signals persisted after the Benjamini-
359 Hochberg correction in the inverse analyses (**Fig. 4h**). Details of the results, including all five
360 different Mendelian randomization estimators, are shown in **Supplementary eFile 18**.

361 Between the nine DNEs and eleven chronic diseases, encompassing brain-related
362 conditions and diseases affecting other organs, we identified a potential causal effect from AD2
363 to AD using the GWAS summary statistics from PGC – the largest sample size ($N=1,126,536$
364 individuals) in the AD case-control study [P-value= 1.74×10^{-4} , OR (95% CI) = 1.25 (1.11, 1.40),
365 number of SNPs=7] (**Fig. 4i**). We didn't detect a causal link in the opposite direction from AD to
366 AD2. This aligns with the endophenotype hypothesis, suggesting that DNEs are situated within
367 the causal pathway from genetics to external phenotypes, such as AD diagnosis and cognitive
368 decline. Details of the results, including all five different Mendelian randomization estimators,
369 are shown in **Supplementary eFile 19**. The results of the sensitivity check are presented in
370 **Supplementary eFigure 14-17**.

371 The Mendelian randomization results further emphasize the potential benefits of overall
372 organ health for brain-related conditions. This highlights the interconnectedness between various
373 organ systems and the brain, underscoring the significance of a holistic health and disease
374 prevention approach.

375 **The nine DNEs and their PRSs significantly improve prediction for 14 systemic diseases** 376 **and mortality**

377 We investigated the added prediction power of the nine DNEs and their respective PRS (**Method**
378 **4h**) for 14 systemic diseases based on the ICD-10 code (**Supplementary eTable 7-8**), 8
379 cognitive scores(**Supplementary eTable 9**), and mortality outcomes (i.e., the date of death). The
380 definition of the patient and healthy control groups and the mortality outcome are presented in
381 **Method 5**. Of note, we did not perform prediction on the four brain diseases (AD, ASD, LLD,
382 and SCZ) due to the small and highly imbalanced sample sizes in the UKBB general population
383 (**Method 1**). As anticipated, the prediction performance across all tasks was modest, considering
384 that the DNEs were derived from specific disease populations.

385 In addition to commonly available features, such as age and sex, we found that AD1,
386 ASD1, LLD1, SCZ1, and SCZ2 provided additional prediction power (i.e., incremental R^2) for
387 many disease categories (**Method 5a**). Across the 14 disease categories, the DNEs showed
388 higher incremental R^2 in mental and behavioral disorders (ICD-10 code: F group) and diseases
389 linked to the central nervous system (ICD-10 code: G group) than other disease categories,
390 proving that the nine DNEs in the general population capture disease-related effects of the four
391 brain diseases. Combining all nine DNEs further improved the incremental R^2 , especially in
392 mental and behavioral disorders ($R^2=1.01\%$, $P\text{-value}=1.74\times 10^{-5}$) and diseases linked to the
393 central nervous system ($R^2=0.63\%$, $P\text{-value}=1.33\times 10^{-5}$) (**Fig. 5a**). The incremental R^2 values for
394 all tests are shown in **Supplementary eTable 7**. All metrics, encompassing sample sizes and
395 incremental R^2 for both the null and alternative models, are outlined in **Supplementary eFile**
396 **20**. Results using only the PRS target population are presented in **Supplementary eFigure 18**.

397 Compared to the nine DNEs, the nine PRSs provided smaller additional prediction power.
398 For example, the PRS for ASD3 explained an additional 0.05% of the variance (incremental R^2)
399 in diseases associated with the blood and immune systems ($P\text{-value}=0.03$), as well as neoplasms
400 ($P\text{-value}=0.04$). Combining all nine PRSs improves the incremental R^2 , particularly in mental
401 and behavioral disorders ($R^2=0.3\%$, $P\text{-value}=0.047$). No results survived multiple comparisons
402 using the Benjamini-Hochberg method (**Fig. 5b**). Detailed results are shown in **Supplementary**
403 **eTable 8** and **eFile 21**.

404 We assessed the prediction ability of support vector machines (SVM) at the individual
405 level to classify the 14 disease categories (**Method 5b**). The highest performance was observed
406 for eye diseases (ICD-codes: H0-5). Age and sex significantly enhanced the classification
407 accuracy. Including age and sex alongside the 9 DNEs and 9 PRSs boosted the classification
408 accuracy from 0.55 to 0.65. The inclusion of PRSs, DNEs, and the combination of both, along
409 with age and sex as features, resulted in improved classification accuracy for mental and
410 behavioral disorders. For example, the accuracy increased from 0.51 to 0.55 and 0.57 for features
411 of age and sex, 9 DNEs, and 9 PRSs, incrementally (**Fig. 5c**). These findings highlight the added
412 value of incorporating the nine DNEs and PRSs in predicting these disease categories. Detailed
413 results are shown in **Supplementary eTable 9a**. The full evaluation metrics of the cross-
414 validated and independent test results are presented in **Supplementary eFile 22**.

415 We examined the predictive capability of these feature sets in estimating 8 cognitive
416 scores (**Method 5c**). The digit symbol substitution test (DSST) demonstrated the highest
417 performance, reaching a Pearson's r of 0.46 (e.g., $P\text{-value}=3.9\times 10^{-189}$ and $\text{MAE}=3.75$ for the
418 feature set of 9 DNE plus covariates) in the independent test dataset using all different sets of
419 features (**Fig. 5d**). The combination of DNEs and PRSs did not notably enhance prediction

420 accuracy. However, contrary to the 14 systemic disease classifications, incorporating the 119
421 GM imaging-derived phenotypes alongside DNEs and PRSs resulted in a 2% increase in the
422 prediction accuracy for fluid intelligence, measured by Pearson's r (**Supplementary eTable 9b**).
423 The full evaluation metrics of the cross-validated and independent test results are presented in
424 **Supplementary eFile 23**.

425 Finally, we evaluated the prediction power of the nine DNEs and PRSs for mortality risk
426 prediction using the Cox regression (**Method 5d**). Among these, SCZ1, SCZ1-PRS, ASD1, and
427 AD1-PRS were significantly associated with the risk of mortality (**Fig. 5e** and **Supplementary**
428 **eTable 10a**). Adding SCZ1, AD1-PRS, ASD1, and SCZ1-PRS to age and sex further improved
429 the prediction, but the performance decreased afterward (**Fig. 5f**). Lastly, incorporating the nine
430 DNEs from the second scan of 1348 participants into the model slightly increased the statistical
431 significance and the HR (**Supplementary eTable 10b** and **c**).

432 **Discussion**

433 This study investigated the manifestation of nine disease-related brain endophenotypes – derived
434 from four case-control studies via semi-supervised AI methods – in the general population of
435 39,178 participants in UKBB. We assessed commonalities and differences among the nine
436 DNEs, their genetic correlates in the general population, their relationships with the multiple
437 human organ systems, and their predictive capacity for 14 systemic disease categories and
438 mortality. Our findings demonstrate the potential of the nine AI-derived DNEs in identifying
439 high-risk individuals within the general population prone to developing the four major brain
440 disorders.

441 442 **Shared neuroanatomical patterns and genetic determinants across the four brain diseases** 443 **in the general population**

444 Understanding the shared disease mechanism of neurodegenerative and neuropsychiatric
445 diseases is a complex and ongoing challenge in medical research^{16,17,42,44–47,66}. Our results
446 suggest that shared underlying mechanisms and genetic factors may contribute to the
447 development and progression of these disorders. This notion of shared disease mechanisms
448 across the four major neurodegenerative and neuropsychiatric diseases, namely ASD, SCZ, LLD,
449 and AD, has garnered considerable attention and reshaped our understanding of these
450 conditions^{16,17}.

451 Despite the inherent heterogeneity among neuroanatomical patterns observed in different
452 brain diseases (**Fig. 2a**), a notable commonality exists regarding their manifestations, which
453 might emanate from underlying mechanisms sharing neuropathologic characteristics and
454 pathways. As an illustration, AD1, LLD2, and SCZ1 exhibited a negative correlation (brain
455 atrophy) with widespread cortical volumes, such as the bilateral insula and middle frontal gyrus.
456 This aligns with expectations, considering that the UKBB population includes individuals
457 primarily from mid to late life (above 45 years). From an etiological standpoint, various factors
458 can contribute to the global cortical volume reduction within the general population, with late-
459 onset neurodegenerative and neuropsychiatric disorders and aging exerting a significant impact.
460 Likewise, ASD2 and SCZ2 exhibited a positive association with the basal ganglia, including the
461 globus pallidum. This could imply the existence of potential protective genetic or environmental
462 factors that collectively contribute to the concept of "brain reserve", which might mitigate
463 volume loss in a portion of the general population. Notably, we previously revealed that
464 individuals predominantly expressing SCZ2 exhibited higher levels of education⁴ and higher
465 remission rates than those primarily influenced by SCZ1. Alternatively, these volume increases
466 might reflect neuropathologic mechanisms, such as disrupted connectivity, which are not
467 necessarily associated with neurodegenerative and neurodevelopmental components related to
468 relatively lower brain volumes. Ultimately, another significant aspect to consider involves the
469 impact of medications prescribed by clinicians, affecting both disease-specific and general
470 populations. Research indicates that antipsychotic medications, commonly prescribed for most
471 individuals with schizophrenia and some with ASD and AD, have been shown to delay brain
472 volume loss in the basal ganglia⁶⁷ and pallidum⁶⁸.

473 The commonalities in neuroanatomical patterns across brain diseases can be attributed to
474 several factors. First, shared genetic factors may influence brain structure and function^{30,32},
475 contributing to similar neuroanatomical alterations across different diseases. Genetically, this
476 was largely evidenced by our genetic correlation (**Fig. 4a**) and colocalization results (**Fig. 4e**).

477 For instance, ASD2 showed prominent positive genetic overlap with SCZ1. Historically, there
478 has been a long-standing association between ASD and SCZ, leading to the notion that autism
479 could be a form of "childhood schizophrenia"⁶⁹. This conceptual link between the two conditions
480 has been debated and discussed. Previous case-control neuroimaging studies demonstrated
481 divergent structural and functional brain patterns in individuals with ASD compared to those
482 with SCZ^{70,71}, largely ignoring the neuroanatomical heterogeneity within each condition. Genetic
483 variants that impact key signaling pathways, synaptic function, and neuronal connectivity^{72,73}
484 could influence multiple disease phenotypes, leading to overlapping neuroanatomical patterns.

485 AD1 also shared genetic similarities with LLD1, both characterized by spatially extensive
486 brain atrophy and increased brain age. Previous studies found a higher prevalence of depressive
487 symptoms and LLD in individuals with AD compared to the general population⁷⁴⁻⁷⁶. The
488 relationship between AD and LLD likely involves multiple factors and may be bidirectional. On
489 the one hand, LLD may increase the risk of developing AD or accelerate the progression of
490 cognitive decline in individuals already affected by AD. On the other hand, AD-related changes
491 in the brain, such as neuroinflammation and neurochemical imbalances, may worsen depressive
492 symptoms in individuals with LLD.

493 Recognizing the shared disease mechanisms across the four brain diseases underscores
494 the importance of a broader perspective on clinical presentations and underlying biological
495 mechanisms. This understanding is important for developing targeted and personalized
496 approaches to patient care, leading to more effective treatments and interventions. Future
497 research may explore disease heterogeneity to transcend traditional classification boundaries and
498 identify data-driven subtypes or dimensions within a transdiagnostic framework⁷⁷.

499

500 **Beyond the brain**

501 Our findings strongly concur with a paradigm shift in treating brain diseases. While the
502 conventional approach has predominantly concentrated on interventions targeting the brain,
503 emerging evidence highlights the critical importance of considering the broader systemic and
504 environmental factors that influence disease onset and progression.

505 Unraveling the intricate interconnections between the brain and other organ systems is
506 crucial in broadening our understanding of brain diseases, as demonstrated by our findings and
507 other findings. The brain does not function in isolation but interacts with and is influenced by
508 various physiological systems throughout the body. Our results showed a close genetic
509 association and causality between the DNEs and the eye, cardiovascular, and pulmonary systems
510 (**Fig. 4b, f, and h**). These findings parallel previous literature. For instance, eye-related
511 pathological changes have been revealed to mirror early signs of neurological and
512 neuropsychiatric conditions⁷⁸. The nervous and cardiovascular systems – the heart-brain axis –
513 are intricately linked, with brain regions controlling heart function via sympathetic and
514 parasympathetic pathways⁷⁹. Dysfunctions in one system can affect the other's function, resulting
515 in brain and cardiovascular diseases. The immune system plays a crucial role in modulating
516 inflammation and neuroinflammation, which are implicated in many brain disorders, such as
517 AD⁸⁰, SCZ⁸¹, and depression⁸². Similarly, the gut-brain axis highlights the bidirectional
518 communication between the gut microbiota and the brain, with emerging evidence linking
519 alterations in the gut microbiome to brain diseases such as Parkinson's disease⁸³ and
520 depression⁸⁴. Understanding and targeting these systemic interactions can modulate disease
521 processes and improve treatment outcomes.

522 Furthermore, considering environmental and lifestyle factors is essential in treating brain
523 diseases⁸⁵. Our previous work¹⁸ has shown that the BAGs of nine human organ systems comply
524 with Cheverud's Conjecture: the phenotypic correlation of two BAGs mirrors their genetic
525 correlations. However, herein we showed that the phenotypic correlation between two DNEs
526 (e.g., ASD1 vs. LLD1) did not reflect their underlying genetic correlation (**Fig. 4a**), indicating
527 potentially strong environmental and lifestyle factors that exert opposite effects on the two
528 DNEs. Furthermore, an interesting observation from our study was that the heritability estimate
529 (h^2) of early-onset diseases, such as ASD, was higher than that of late-onset diseases, such as
530 LLD, within the three neuropsychiatric disorders. This finding suggests that genetic factors play
531 a more prominent role in developing ASD at a younger age. In contrast, other factors, such as
532 environmental influences, socioeconomic factors, and lifestyle choices, may have a stronger
533 impact on developing LLD later in life. These differential heritability patterns shed light on the
534 complex interplay between genetic and non-genetic factors in the underlying disease mechanism
535 of neurodegenerative and neuropsychiatric disorders across different stages of life. These
536 heritability patterns aligned with a previous study that examined multiple GWAS drawn from
537 more than 200,000 patients for 25 brain-associated disorders and 17 phenotypes¹⁷.

538 In conclusion, going beyond the brain is crucial for understanding and treating brain
539 diseases. By considering the connections between the brain and other organ systems,
540 understanding the impact of environmental and lifestyle factors, and harnessing the power of
541 advanced AI technologies, we can develop more effective and personalized approaches to
542 prevent, diagnose, and treat brain diseases.

543

544 **AI-derived DNEs for precision diagnostics in the general population**

545 The present study leverages cutting-edge, semi-supervised AI methods²⁴ and open science
546 advancements to enhance our understanding of disease heterogeneity in neurodegenerative and
547 neuropsychiatric disorders. In this context, implementing these AI-derived DNEs at early disease
548 or preclinical stages – in the general population – may facilitate the identification of individuals
549 at risk, and the initiation of proactive interventions before the onset of noticeable symptoms,
550 likely leading to more effective treatments and interventions and better outcomes.

551 The proposed AI-derived DNEs capture intricate brain structure and function variations,
552 often subtle and spatially complex, which traditional diagnostic methods and case-control studies
553 may overlook. By quantifying the neuroanatomical patterns associated with specific brain
554 disorders, DNEs may offer a personalized disease vulnerability assessment, inform interventions
555 at early preclinical stages, and potentially prevent or delay the onset of symptoms. At the
556 individual level, integrating genetic information (i.e., PRSs) with DNEs significantly improves
557 prediction performance for 14 systemic diseases and mortality outcomes (**Fig. 5**). In addition, our
558 Mendelian randomization analyses supported the well-established endophenotype hypothesis in
559 genetic psychiatry²⁵ – endophenotype in psychiatric disorders resides inside the causal pathway
560 from underlying genetics to their exo-phenotypes (i.e., the disease syndrome itself), thereby
561 being closer to its disease mechanisms. We found that AD2, characterized by focal medial
562 temporal lobe atrophy, exerted a causal relationship with AD. However, we did not find evidence
563 of a reverse causal relationship, suggesting that the underlying genetics may influence the
564 development of AD through the DNE, although it may not be the exclusive pathway contributing
565 to the disease. This highlights the role of genetics in influencing the disease process, particularly
566 through the identified DNE, shedding light on potential pathways and mechanisms involved in
567 AD development.

568

569 **Limitation**

570 The present study has several limitations. Firstly, the genetic analysis focused exclusively on
571 common genetic variants. Future investigations should explore the contribution of rare variants
572 to these brain diseases. Secondly, it is important to recognize that our GWAS analyses
573 predominantly involved participants of European ancestry, limiting the generalizability of the
574 genetic findings to other populations with different ancestral backgrounds. Further research
575 efforts are necessary to collect more diverse genetic data and include underrepresented racial and
576 ethnic groups to enhance the generalizability of the findings. Additionally, the validation of the
577 nine DNEs would benefit from additional longitudinal analyses. Fortunately, ongoing efforts to
578 collect longitudinal brain MRI data in UKBB⁸⁶ hold promise for providing valuable insights to
579 the scientific community and advancing the field of precision medicine. Furthermore, more
580 advanced methodological developments will be developed and integrated within our semi-
581 supervised clustering learning framework to alleviate potential domain shifts⁸⁷. Finally, our
582 future research will incorporate multimodal imaging to generate DNEs sensitive to a broader
583 range of brain alterations, including macrostructural volumetric changes, functional disruptions,
584 and structural network abnormalities.

585

586 **Outlook**

587 Together, our AI-derived DNEs have emerged as novel instruments for precision medicine. By
588 capturing the complexity and heterogeneity of brain disorders, DNEs provide a better
589 understanding of disease pathology, facilitate personalized risk assessment, and hold promise for
590 targeted interventions and population selection.

591 **Methods**

592 **Method 1: Study populations**

593 Our previous studies used semi-supervised AI models to define the nine DNEs from four disease
594 case-control populations. These populations consisted of 865 healthy controls (CN), 1096
595 individuals with mild cognitive impairment (MCI), and 414 AD patients from ADNI²² for AD1
596 and AD2, 362 typically developing controls, and 307 patients with autism spectrum disorder
597 (ASD) from ABIDE²³ for ASD1-3, 495 healthy controls and 501 LLD patients from the LLD
598 study³ for LLD1-2, and 364 healthy controls and 307 SCZ patients from PHENOM⁴ for SCZ1-2.
599 For more detailed information about the characteristics of the study populations, please refer to
600 the original papers.

601 The trained AI models were then applied to the UKBB general population as independent
602 data. UKBB is a population-based study of approximately 500,000 people recruited from the
603 United Kingdom between 2006 and 2010. The UKBB study has ethical approval, and the ethics
604 committee is detailed here: [https://www.ukbiobank.ac.uk/learn-more-about-uk-](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee)
605 [biobank/governance/ethics-advisory-committee](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee). The current study analyzed 39,178 multimodal
606 brain MRI data from UKBB. T1-weighted MRI data were locally processed at the University of
607 Pennsylvania; imaging-derived phenotypes (IDP) from diffusion and resting-state functional
608 MRI were downloaded from UKBB. In addition, we processed the imputed genotype data²⁸ from
609 UKBB for GWAS analyses. Last, other clinical traits were also analyzed, including phenotypes
610 related to nine human organ systems. The current work was performed under application
611 numbers 35148 and 60698. To unbiasedly evaluate the PRS and machine learning models, we
612 defined the following populations:

- 613 • *Disease case-control populations*: The four datasets used to train the AI models and
614 define the nine DNEs from four brain diseases.
- 615 • *Independent UKBB general population (N=39,178)*: The UKBB population in which the
616 trained AI models were applied to derive the nine DNEs.
- 617 • *PRS base/target population (split1/split2) (N=15,968)*: the UKBB population was
618 divided into two splits (split1 vs. split2) in the split-sample GWAS. To derive the PRS,
619 we used the GWAS from split1 as the base data and split2 as the target data. All disease
620 and mortality prediction tasks involving PRS used only the PRS target population
621 (N=15,968).

622 Within the UKBB general population, individuals with various diseases are classified
623 under the ICD-10 code (Data field: 41270), though often in smaller numbers. Among the 39,178
624 participants from the UK Biobank included in our study, we outline the sample sizes and criteria
625 for the healthy control group, as well as those with AD, ASD, LLD (encompassing a broad
626 spectrum of depression), and SCZ, all categorized according to the ICD-10 code:

- 627 • *Healthy control*: 6390 participants without any ICD-10-based disease diagnoses from the
628 data field: 41270 from the training/validation/test dataset in **Method 5**.
- 629 • *AD*: 23 AD patients based on the ICD-10 code (G30).
- 630 • *ASD*: 6 ASD patients based on the ICD-10 code (F84.0).
- 631 • *LLD*: 1329 patients based on the ICD-10 code (F32).
- 632 • *SCZ*: 23 SCZ patients based on the ICD-10 code (F20).
- 633 • *The 14 systemic disease categories*: we used the ICD-10 code to define the disease
634 groups. The exact ICD-10 code for each category is detailed in **Fig. 5a**.

635

636

637

638 **Method 2: Semi-supervised AI methods to derive the nine DNEs**

639 The methodologies used in the current study to derive the nine DNEs belong to the semi-
640 supervised learning algorithms (**Fig. 1a**) pioneered by our group. Refer to a review for details of
641 this type of modeling. In particular, the current study employed the HYDRA³¹ and Surreal-
642 GAN¹⁵ models.

643

644 **(a): Surreal-GAN:** Surreal-GAN¹⁵ dissects underlying disease-related heterogeneity via a deep
645 representation learning approach, instead of the discriminative SVM, under the principle of semi-
646 supervised clustering – the "*I-to-k*" mapping. The methodological advance of this method is that
647 Surreal-GAN models disease heterogeneity as a continuous dimensional representation, enforces
648 monotone disease severity in each dimension, and allows the non-exclusive manifestation of all
649 dimensions in the same participant (**Supplementary eMethod 1a**).

650 We encapsulated the characteristics of the AD1 and AD2 derived by Surreal-GAN from
651 the disease-specific population. AD1 represents a "diffuse-AD" dimension characterized by
652 widespread brain atrophy, whereas AD2, described as a "medial temporal lobe-AD" dimension,
653 exhibits focal atrophy in the medial temporal lobe (MTL)¹.

654

655 **(b): HYDRA:** HYDRA leverages a widely used discriminative method, i.e., support vector
656 machines (SVM), to seek the "*I-to-k*" mapping. The novelty is that HYDRA extends multiple
657 linear SVMs to the non-linear case piecewise, thereby simultaneously serving for classification
658 and clustering. Specifically, it constructs a convex polytope by combining the hyperplane from *k*
659 linear SVMs, separating the CN group from the *k* subpopulation of the PT (patient) group.
660 Intuitively, each face of the convex polytope can be regarded to encode each subtype, capturing a
661 distinct disease effect (**Supplementary eMethod 1b**).

662 We summarized the main characteristics of the ASD1-3, LLD1-2, and SCZ1-2 derived by
663 HYDRA in the disease-specific populations. ASD1 showed correlations with reduced brain
664 volume, decreased cognitive function, and genetic variants related to aging. ASD2 exhibited
665 enlarged subcortical volumes and was linked to the use of antipsychotic medication. ASD3 was
666 identified by expanded cortical volumes and higher performance in nonverbal cognitive tasks².
667 LLD1 displayed relatively maintained brain structure without disruptions in white matter
668 compared to healthy control individuals, whereas LLD2 exhibited extensive brain atrophy,
669 disruptions in white matter integrity, cognitive decline, and increased severity of depression³.
670 SCZ1 exhibited widespread reduction in grey matter volumes, particularly notable in the
671 thalamus, nucleus accumbens, medial temporal, medial prefrontal/frontal, and insular cortices.
672 SCZ2 displayed increased volume in the basal ganglia and internal capsule, while other brain
673 volumes remained relatively normal⁴.

674

675

676 **Method 3: Imaging analyses**

677 **(a): T1-weighted MRI processing:** All images were first corrected for magnetic field intensity
678 inhomogeneity.⁸⁸ A deep learning-based skull stripping algorithm was applied to remove extra-
679 cranial material. In total, 145 IDPs were generated in gray matter (GM, 119 ROIs), white matter

680 (WM, 20 ROIs), and ventricles (6 ROIs) using a multi-atlas label fusion method from the
681 MUSE atlas.⁸⁹ The ROIs were fit to the four machine learning models to derive the nine DNEs.
682 The imaging quality check is detailed in **Supplementary eMethod 2**. The other IDPs derived
683 from other MRI modalities [i.e., diffusion (category code: 135) and resting-state MRI (data-field
684 code: 25750)] were downloaded from UKBB.

685
686 **(b): Neuroanatomical pattern of the nine DNEs:** We assessed the neuroanatomical patterns
687 exhibited by the nine DNEs within the general population. Since the DNEs were defined based
688 on the 119 GM ROIs obtained from T1-weighted MRI scans, we aimed to test whether these
689 patterns observed in the disease populations were manifested in the general population. To this
690 end, we used a linear regression model in which each DNE was treated as the dependent
691 variable, while the ROI, age, age-squared, sex, age x sex interaction, age-squared x sex
692 interaction, intracranial volume, brain positions in the scanner (lateral, transverse, and
693 longitudinal; Field ID: 25756-25758), and head motion were considered independent variables
694 and covariates. We employed the Bonferroni method for multiple comparisons and reported
695 significant results accordingly.

696
697 **(c): PWAS for the nine DNEs:** We performed PWAS to associate the nine DNEs to each of the
698 611 additional phenotypes. PWAS excluded the 119 GM ROIs utilized to derive the nine DNEs
699 to prevent any potential circular effects. Instead, the analysis incorporated IDPs from other
700 modalities, such as diffusion and resting-state functional MRI. The same linear regression
701 models and multiple comparison corrections were employed as in **Method 3b**.

702 To check the robustness of our PWAS results, we also performed two sensitivity checks:
703 *i)* sex-stratified PWAS for males and females, and *ii)* split-sample PWAS by randomly dividing
704 the entire population into two splits (sex and age did not significantly differ).

706 **Method 4: Genetic analyses**

707 We used the imputed genotype data for all genetic analyses, and our quality check pipeline
708 resulted in 31,929 participants with European ancestry and 6,477,810 SNPs. First, we excluded
709 36,394 related individuals (up to 2nd-degree) from the full UKBB sample ($N \sim 500k$) using the
710 KING software for family relationship inference⁹⁰. We then removed duplicated variants from all
711 22 autosomal chromosomes. Individuals whose genetically identified sex did not match their
712 self-acknowledged sex were removed. Other excluding criteria were: *i)* individuals with more
713 than 3% of missing genotypes; *ii)* variants with minor allele frequency (MAF) of less than 1%;
714 *iii)* variants with larger than 3% missing genotyping rate; *iv)* variants that failed the Hardy-
715 Weinberg test at 1×10^{-10} . The Hardy-Weinberg test removes the SNPs that deviate from the
716 expected HWE frequency, ensures the integrity of the genetic data, reduces false-positive
717 findings, and improves the overall robustness of the GWAS results. To adjust for population
718 stratification,⁹¹ we derived the first 40 genetic principle components (PC) using the FlashPCA
719 software⁹². Details of the genetic quality check protocol are described elsewhere.

720
721 **(a): GWAS:** For GWAS, we ran a linear regression using Plink⁹³ for each DNE, controlling for
722 confounders of age, age-squared, sex, age x sex interaction, age-squared x sex interaction, the
723 first 40 genetic principal components, total intracranial volume, three brain position parameters
724 in the scanner, and head motion were included, as suggested by a previous study³⁰. We adopted

725 the genome-wide P-value threshold (5×10^{-8}) and annotated independent genetic signals
726 considering linkage disequilibrium (see below).

727 To check the robustness of our GWAS results, we also performed several sensitivity
728 checks: *i)* fastGWA^{40,41} for a generalized mix effect model, *ii)* sex-stratified GWAS for males
729 and females, *iii)* split-sample GWAS by randomly dividing the entire population into two splits
730 (sex and age did not significantly differ), *iv)* comparison of the GWAS results using the 1348
731 participants (i.e., 1116 European ancestry) that were collected for baseline and longitudinal scans
732 from UKBB, *v)* non-European GWAS ($N=4783$), *vi)* independent GWAS on ADNI whole-
733 genome sequencing data ($N=1555$) on AD1 and AD2, *vii)* concordance with six European
734 ancestry GWAS from PGC, including AD, ADHD, ASD, BIP, OCD, and SCZ (**Supplementary**
735 **eTable 3a**).

736
737 **(b): SNP-based heritability:** We estimated the SNP-based heritability (h^2) using GCTA³⁹ with
738 the same covariates as in GWAS. GCTA estimates the SNP-based heritability using a method
739 called restricted maximum likelihood (REML) to quantify the proportion of phenotypic variance
740 in a trait that the additive effects of all common SNPs can explain, which was claimed to address
741 the “missing heritability”. The main steps involved in GCTA include constructing the genetic
742 relationship matrix, modeling phenotypic variance, and using REML to estimate the h^2 .

743
744 **(c): Annotation of genomic loci:** The annotation of genomic loci and mapped genes was
745 performed via FUMA⁹⁴. For the annotation of genomic loci, FUMA first defined lead SNPs
746 (correlation $r^2 \leq 0.1$, distance < 250 kilobases) and assigned them to a genomic locus (non-
747 overlapping); the lead SNP with the lowest P-value (i.e., the top lead SNP) was used to represent
748 the genomic locus. For gene mappings, three different strategies were considered. First,
749 positional mapping assigns the SNP to its physically nearby genes (a $10 \square$ kb window by default).
750 Second, eQTL mapping annotates SNPs to genes based on eQTL associations using the GTEx v8
751 data⁹⁵. Finally, chromatin interaction mapping annotates SNPs to genes when there is a
752 significant chromatin interaction between the disease-associated regions and nearby or distant
753 genes⁹⁴. The definition of top lead SNP, lead SNP, independent significant SNP, and candidate
754 SNP can be found in **Supplementary eMethod 3**.

755 To determine if a genomic locus is new (i.e., newly discovered in our study), we used
756 FUMA to query the candidate SNPs, independent significant SNPs, and top lead SNP in the
757 EMBL-EBI GWAS Catalog, taking LD into account. For these new loci, we further manually
758 queried the non-significant SNPs in LD ($r^2 > 0.1$) with these SNPs directly on the GWAS Catalog
759 platform on 29th October 2024. A locus is considered new if no previous GWAS has identified
760 associations with any of these SNPs. It is worth noting that the current definition of new loci is
761 not completely exhaustive and objective, as new GWAS data are being collated into the GWAS
762 Catalog, while other public data platforms (such as the GWAS Catalog and the IEU Open
763 GWAS Project) are not considered.

764
765 **(d): Phenome-wide association queries for the identified loci in the GWAS Catalog:** We
766 queried the candidate and significant independent SNPs, considering LD (**Supplementary**
767 **eMethod 3**), within each locus in the EMBL-EBI GWAS Catalog (query date: 2nd June 2023
768 and also via FUMA version: v1.5.4) to determine their previously identified associations with
769 any other traits. For these associated traits, we further mapped them into several high-level
770 categories for visualization purposes. We categorized these traits based on their primary affected

771 organ systems, with examples including blood pressure under cardiovascular, brain MRI-derived
772 measures under brain, and AD under neurodegenerative disorders. Other platforms, such as the
773 GWAS Atlas (<https://atlas.ctglab.nl/PheWAS>), used a similar categorization approach; we
774 followed a similar approach to curating the high-level categories for the trait-category mapping.
775

776 **(e): Genetic correlation:** We used the LDSC³⁸ software to estimate the pairwise genetic
777 correlation (g_c) between each pair of DNEs, as well as between the nine DNEs and 9 BAGs of
778 multiple organ systems from our previous work¹⁸ and 6 neurodegenerative and neuropsychiatric
779 disorders from PGC (**Supplementary eTable 3a**). We used the precomputed LD scores from the
780 1000 Genomes of European ancestry. To ensure the suitability of the GWAS summary statistics,
781 we first checked that the selected study's population was European ancestry; we then guaranteed
782 a moderate SNP-based heritability h^2 estimate. Notably, LDSC corrects for sample overlap and
783 provides an unbiased estimate of genetic correlation⁹⁶. Benjamini-Hochberg procedure was
784 performed to account for multiple comparisons.
785

786 **(f): Bayesian colocalization:** We used the R package (*coloc*) to investigate the genetic
787 colocalization signals between two traits at each genomic locus. We employed the Fully
788 Bayesian colocalization analysis using Bayes Factors (*coloc.abf*). This method examines the
789 posterior probability (PP.H4.ABF: Approximate Bayes Factor) to evaluate hypothesis $H4$, which
790 suggests the presence of a single shared causal variant associated with both traits within a
791 specific genomic locus. To determine the significance of the $H4$ hypothesis, we set a threshold of
792 $PP.H4.ABF > 0.8$ ⁵². All other parameters (e.g., the prior probability of p_{12}) were set as default. We
793 also performed relevant sensitivity analyses to check the robustness of our findings. For each
794 pair of traits, the genomic locus ($N > 100$ SNPs) was defined by default from FUMA on the nine
795 DNEs, and then the *coloc* package extracted and harmonized the GWAS summary statistics
796 within this locus for the other trait.
797

798 **(g): Two-sample bidirectional Mendelian randomization:** We did not perform causal
799 inference between each pair of DNEs due to the overlapped populations and low sample sizes in
800 split-sample analyses.

801 We employed a bidirectional, two-sample Mendelian randomization using the
802 TwoSampleMR package⁶⁴ to infer the causal relationships between the nine DNEs and the eight
803 BAGs across nine human organ systems¹⁸ (excluding the brain). The forward and inverse
804 Mendelian randomization was performed between each trait pair by switching the exposure and
805 outcome variables. We applied five different Mendelian randomization methods and reported the
806 results of inverse variance weighted (IVW) in the main text and the four others (i.e., Egger,
807 weighted median, simple mode, and weighted mode estimators) in the supplement.

808 We then performed Mendelian randomization between the nine DNEs and eleven chronic
809 diseases spanning the whole-body system. These diseases include four diseases from PGC (the
810 ASD and OCD GWAS summary statistics did not provide the allele frequency information) and
811 seven diseases unbiasedly curated in our previous work¹⁸, which detailed a systematic procedure
812 to choose the appropriate traits. After harmonizing their GWAS summary statistics (using the
813 function *harmonise_data* from 2SampleMR), this resulted in 11 clinical traits with at least six
814 valid IVs (i.e., SNPs). The clinical traits included in our Mendelian randomization are presented
815 in **Supplementary eTable 11**. Benjamini-Hochberg correction was performed for all tested
816 traits.

817 We performed several sensitivity analyses. First, a heterogeneity test was performed to
818 check for violating the IV assumptions. Horizontal pleiotropy was estimated to navigate the
819 violation of the IV's exclusivity assumption⁹⁷ using a funnel plot, single-SNP Mendelian
820 randomization approaches, and Mendelian randomization Egger estimator⁹⁸. Moreover, the
821 leave-one-out analysis excluded one instrument (SNP) at a time and assessed the sensitivity of
822 the results to individual SNP.

823
824 **(h): PRS calculation for the nine DNEs:** We calculated the PRS using the GWAS results from
825 the split-sample analyses. The weights of the PRS were defined based on split1 data (base data),
826 and the split2 GWAS summary statistics were used as the target data for PRS calculation. The
827 QC steps for the base data are as follows: *i*) removal of duplicated and ambiguous SNPs for the
828 base data; *ii*) clumping the base GWAS data; *iii*) pruning to remove highly correlated SNPs in
829 the target data; *iv*) removal of high heterozygosity samples in the target data; *v*) removal of
830 duplicated, mismatching and ambiguous SNPs in the target data. After rigorous QC, we used
831 PLINK to generate PRS for the split2 population by adopting the classic C+T method (clumping
832 + thresholding). To determine the "best-fit" PRS, we performed a linear regression using the PRS
833 calculated at different P-value thresholds (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), controlling for age,
834 sex, intracellular volume, and the first forty genetic PCs. For each DNE-PRS, we chose the P-
835 value threshold with the highest incremental R^2 (**Supplementary eFigure 19**).

836 We also tested the PRS-CS⁹⁹ method to derive the nine PRS, which infers posterior SNP
837 effect sizes under continuous shrinkage priors using GWAS summary statistics and an LD
838 reference panel (i.e., UKBB reference). Compared to the PLINK method, PRS-CS obtained
839 higher incremental R^2 to explain the 9 DNEs in the split2 data (1.99% vs. 0.52%, P-value=0.003
840 for two-sample t-test, **Supplementary eFigure 20**; P-value thresholding was explicitly
841 employed for PRS-CS to ensure a fair comparison). Second, the 9 PRSs from PLINK and PRS-
842 CS were highly concordant and correlated with each other (Pearson's r correlation=0.98, P-
843 value=0.000007, **Supplementary eFigure 21**). Last but not least, the 9 PRSs from PRS-CS did
844 not predict well for mental and behavioral disorders (ICD-10 code: F group) and diseases linked
845 to the central nervous system (ICD-10 code: G group). That is, the highest incremental R^2 was
846 obtained for ear diseases (H6-H9) using all combined 9 PRSs (**Supplementary eFigure 22**).
847 Therefore, we chose to use the 9 PRSs derived from PLINK for all results presented in **Fig. 5**.
848

849 **Method 5: Disease, cognition, and mortality outcome prediction.**

850 We employed logistic regression to calculate the incremental R-squared (R^2) statistics of the nine
851 DNEs and PRSs to predict 14 disease categories (**a**), support vector machines to classify the
852 healthy control participants from the disease groups (**b**), and Cox proportional hazard model to
853 predict mortality outcomes (**c**). The patients for the 14 disease categories were defined based on
854 the ICD-10 code from the UKBB website (Data field: 41270). The healthy control group
855 included participants without any ICD-10-based disease diagnoses. The cognitive function data
856 included 8 cognitive scores (Category: 100026), which were detailed in **Supplementary eFile 23**.
857 The mortality outcome refers to the date of death:
858 <https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40000>.
859

860 **(a): Pseudo R-squared (R^2) statistics of the logistic regression:** We built a null model by
861 including age, sex, and intracranial volume as predictors and the disease as the outcome variable.

862 The alternative model took the disease-specific DNE or PRS as one additional predictor. The
863 incremental R^2 was calculated as the difference between the pseudo R^2 of the alternative model
864 and that of the null model, implemented by the *PseudoR2* function from the *DescTools* R
865 package (v 0.99.38). For the nine PRSs, we used the PRS target sample ($N=15,891$). For the nine
866 DNEs, we calculated the incremental R^2 using the entire UKBB sample ($N=39,178$) and the PRS
867 target sample ($N=15,891$). We reported the incremental R^2 of the DNE/PRS in the main
868 manuscript (**Fig. 5a** and **b**). Other metrics, including R^2 of the null and the alternative model,
869 sample sizes, and the β values of other covariates, are presented in **Supplementary eFile 20-21**.
870

871 **(b): Support vector machines to classify patients vs. controls:** Using the PRS target sample
872 ($N=15,891$), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV
873 training/validation/test datasets) to select the hyperparameter C in SVM. In addition, we held out
874 5581 participants as an independent test dataset. In **Fig. 5c**, we only presented the classification
875 accuracy from the independent test dataset. The nested cross-validation (CV) procedure¹⁰⁰
876 involved an outer loop repeated 50 times, where 80% of the data were randomly selected for
877 training/validation and 20% for testing. Within each outer loop iteration, an inner loop used 80%
878 of the training/validation data for a 10-fold training/validation split. Critically, the model trained
879 on the training/validation/test datasets generalized to the independent test dataset (**Fig. 5c**).
880 **Supplementary eFile 22** contains various metrics, including balanced accuracy, sensitivity,
881 specificity, negative predictive value (NPV), positive predictive value (PPV), and sample sizes
882 for the independent dataset (*Ind. accuracy*) and the CV training/validation/test datasets (*CV*
883 *accuracy*). We did not statistically compare the performance between different machine learning
884 models as this is a complex matter without a universal solution. A standard t -test on cross-
885 validation results is too liberal and should not be applied, as shown by Nadeau and Bengio¹⁰¹.
886 The corrected resampled t -test¹⁰¹ was proposed, but it depends on the data and the cross-
887 validation setup.
888

889 **(c): Support vector regression to predict cognitive scores:** Using the PRS target sample
890 ($N=15,891$), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV
891 training/validation/test datasets) to select the hyperparameter C in SVM. In addition, we held out
892 5581 participants (some had missing values depending on specific cognitive scores) as an
893 independent test dataset (*Ind. r*). In **Fig. 5d**, we only presented Pearson's r from the independent
894 test dataset. The same nested CV procedure was used, as mentioned above. Likewise,
895 **Supplementary eFile 23** encompasses a range of metrics, including mean absolute error, P-
896 values, and sample sizes, pertaining to the independent dataset (*Ind. r*) and the CV
897 training/validation/test datasets (*CV r*).
898

899 **(d): Cox proportional hazard model to predict the date of death:** To evaluate the predictive
900 capacity of individual DNE and PRS for mortality risk, we employed a Cox proportional hazard
901 model while adjusting for covariates such as age and sex. The hazard ratio (HR) was calculated
902 and reported as the effect size measure that indicates the influence of each DNE or PRS on
903 mortality risk. Furthermore, we incrementally added the most predictive DNE or PRS to the Cox
904 model to determine when the model's performance reached saturation. The concordance index
905 (CI) was utilized to assess the model's performance using a 5-fold cross-validation procedure.
906 All survival analyses were conducted using the *lifelines* (v0.25.7) Python package.

907 **Data Availability**

908 The GWAS summary statistics and pre-trained AI models from this study are publicly accessible
909 via the MEDICINE Knowledge Portal (<https://labs-laboratory.com/medicine/>) and Synapse
910 (<https://www.synapse.org/Synapse:syn64923248/wiki/630992>). Genomic loci annotation used
911 data from FUMA (<https://fuma.ctglab.nl/>). UKBB data can be requested at
912 <https://www.ukbiobank.ac.uk/>. GWAS summary data from the Psychiatric Genomics
913 Consortium (PGC) can be accessed at <https://pgc.unc.edu/>.

914 **Code Availability**

915 The software and resources used in this study are all publicly available:

- 916 • *HYDRA*: <https://github.com/anbai106/mlni>, DNEs for ASD1-3, LLD1-2, SCZ1-2
- 917 • *Surreal-GAN*: <https://github.com/zhijian-yang/SurrealGAN>, DNEs for AD1-2
- 918 • *MLNI*: <https://github.com/anbai106/mlni>, SVM classification, cognitive regression
- 919 • *PLINK*: <https://www.cog-genomics.org/plink/>, GWAS, PRS
- 920 • *FUMA*: <https://fuma.ctglab.nl/>, gene mapping, genomic locus annotation
- 921 • *GCTA*: <https://yanglab.westlake.edu.cn/software/gcta/#Overview>, heritability estimates,
- 922 and fastGWA
- 923 • *LDSC*: <https://github.com/bulik/ldsc>, genetic correlation, partitioned heritability
- 924 • *TwoSampleMR*: <https://mrcieu.github.io/TwoSampleMR/index.html>, MR
- 925 • *Coloc*: <https://chr1swallace.github.io/coloc/>, Bayesian colocalization
- 926 • *PRS-CS*: <https://github.com/getian107/PRSes>, PRS
- 927 • *Lifelines*: <https://lifelines.readthedocs.io/en/latest/>, Survival analyses
- 928 • *DescTools*: <https://cran.r-project.org/web/packages/DescTools/index.html>, Incremental
- 929 R^2 analysis
- 930

931 **Competing Interests**

932 None

933

934 **Authors' contributions**

935 Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the
936 data and the accuracy of the data analysis.

937 *Study concept and design:* Wen, Davatzikos

938 *Acquisition, analysis, or interpretation of data:* all authors

939 *Drafting of the manuscript:* Wen

940 *Critical revision of the manuscript for important intellectual content:* all authors

941 *Statistical analysis:* Wen

942 **References**

- 943 1. Wen, J. *et al.* Genetic and clinical correlates of two neuroanatomical AI dimensions in the
944 Alzheimer's disease continuum. *Transl Psychiatry* **14**, 1–14 (2024).
- 945 2. Hwang, G. *et al.* Assessment of Neuroanatomical Endophenotypes of Autism Spectrum
946 Disorder and Association With Characteristics of Individuals With Schizophrenia and the
947 General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.
- 948 3. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
949 Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
950 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 951 4. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using
952 machine learning. *Brain* **143**, 1027–1038 (2020).
- 953 5. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of
954 neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* **9**, 4273 (2018).
- 955 6. Yang, Z. *et al.* A deep learning framework identifies dimensional representations of
956 Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).
- 957 7. Zhang, X. *et al.* Bayesian model reveals latent atrophy factors with dissociable cognitive
958 trajectories in Alzheimer's disease. *Proc Natl Acad Sci USA* **113**, E6535–E6544 (2016).
- 959 8. Vogel, J. W. *et al.* Four distinct trajectories of tau deposition identified in Alzheimer's
960 disease. *Nat Med* **27**, 871–881 (2021).
- 961 9. Wen, J. *et al.* Multi-scale semi-supervised clustering of brain images: Deriving disease
962 subtypes. *Med Image Anal* **75**, 102304 (2021).
- 963 10. Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease: A
964 systematic review and meta-analysis. *Neurology* **94**, 436–448 (2020).

- 965 11. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 966 12. Davatzikos, C. *et al.* Precision diagnostics based on machine learning-derived imaging
967 signatures. *Magnetic Resonance Imaging* **64**, 49–61 (2019).
- 968 13. Leonenko, G. *et al.* Identifying individuals with high risk of Alzheimer’s disease using
969 polygenic risk scores. *Nat Commun* **12**, 4506 (2021).
- 970 14. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using
971 machine learning. *Brain* **143**, 1027–1038 (2020).
- 972 15. Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN:Semi-Supervised Representation
973 Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*
974 (2021).
- 975 16. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative
976 diseases. *Nat Commun* **13**, 4314 (2022).
- 977 17. Anttila, V. Analysis of shared heritability in common disorders of the brain. *Science* **360**,
978 eaap8757 (2018).
- 979 18. Wen, J. *et al.* The genetic architecture of biological age in nine human organ systems. *Nat*
980 *Aging* 1–18 (2024) doi:10.1038/s43587-024-00662-8.
- 981 19. Wen, J. Multiorgan biological age shows that no organ system is an island. *Nat Aging* 1–2
982 (2024) doi:10.1038/s43587-024-00690-4.
- 983 20. Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* **15**,
984 2604 (2024).
- 985 21. Boquetipujadas, A. *et al.* MUTATE: A Human Genetic Atlas of Multi-organ AI
986 Endophenotypes using GWAS Summary Statistics. 2024.06.15.24308980 Preprint at
987 <https://doi.org/10.1101/2024.06.15.24308980> (2024).

- 988 22. Petersen, R. C. *et al.* Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical
989 characterization. *Neurology* **74**, 201–209 (2010).
- 990 23. Di Martino, A. *et al.* Enhancing studies of the connectome in autism using the autism brain
991 imaging data exchange II. *Sci Data* **4**, 170010 (2017).
- 992 24. Wen, J. *et al.* Subtyping Brain Diseases from Imaging Data. in *Machine Learning for Brain*
993 *Disorders* (ed. Colliot, O.) 491–510 (Springer US, New York, NY, 2023). doi:10.1007/978-
994 1-0716-3195-9_16.
- 995 25. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–
996 797 (2010).
- 997 26. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental
998 Disorders. *Annual Review of Clinical Psychology* **2**, 267–290 (2006).
- 999 27. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and
1000 strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).
- 1001 28. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
1002 *Nature* **562**, 203–209 (2018).
- 1003 29. Alfaro-Almagro, F. *et al.* Image processing and Quality Control for the first 10,000 brain
1004 imaging datasets from UK Biobank. *Neuroimage* **166**, (2018).
- 1005 30. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK
1006 Biobank. *Nature* **562**, 210–216 (2018).
- 1007 31. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and
1008 genetic patterns through a multiple max-margin discriminative analysis framework.
1009 *NeuroImage* **145**, 346–364 (2017).

- 1010 32. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain.
1011 *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).
- 1012 33. Guan, H. & Liu, M. Domain Adaptation for Medical Image Analysis: A Survey. *IEEE*
1013 *Trans Biomed Eng* **69**, 1173–1185 (2022).
- 1014 34. Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: Practical
1015 in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*
1016 **61**, 1000–1016 (2012).
- 1017 35. Joseph, C., Wang, L., Wu, R., Manning, K. J. & Steffens, D. C. Structural brain changes
1018 and neuroticism in late-life depression: a neural basis for depression subtypes. *Int*
1019 *Psychogeriatr* **33**, 515–520 (2021).
- 1020 36. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of
1021 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.
- 1022 37. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK
1023 Biobank participants. *Nat Commun* **13**, 7839 (2022).
- 1024 38. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
1025 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 1026 39. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
1027 Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).
- 1028 40. Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool
1029 for biobank-scale data. *Nat Genet* **53**, 1616–1621 (2021).
- 1030 41. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale
1031 data. *Nat Genet* **51**, 1749–1755 (2019).

- 1032 42. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
1033 identifies new risk loci for Alzheimer’s disease. *Nat Genet* **53**, 1276–1282 (2021).
- 1034 43. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the
1035 genetic architecture and implicate several cognitive domains. *Nat Genet* **55**, 198–208
1036 (2023).
- 1037 44. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder.
1038 *Nat Genet* **51**, 431–444 (2019).
- 1039 45. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder
1040 cases provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).
- 1041 46. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
1042 schizophrenia. *Nature* **604**, 502–508 (2022).
- 1043 47. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-
1044 GC) and OCD Collaborative Genetics Association Studies (OC GAS). Revealing the
1045 complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol*
1046 *Psychiatry* **23**, 1181–1188 (2018).
- 1047 48. O’Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium.
1048 *World Psychiatry* **14**, 291–293 (2015).
- 1049 49. Cheverud, J. M. A comparison of genetic and phenotypic correlations. *Evolution* **42**, 958–
1050 968 (1988).
- 1051 50. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
1052 Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 1053 51. McCutcheon, R. A., Krystal, J. H. & Howes, O. D. Dopamine and glutamate in
1054 schizophrenia: biology, symptoms and treatment. *World Psychiatry* **19**, 15–33 (2020).

- 1055 52. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
1056 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 1057 53. Hordyjewska-Kowalczyk, E. *et al.* Functional analysis of novel RUNX2 mutations
1058 identified in patients with cleidocranial dysplasia. *Clin Genet* **96**, 429–438 (2019).
- 1059 54. Wamsley, B. *et al.* Molecular cascades and cell type–specific signatures in ASD revealed
1060 by single-cell genomics. *Science* **384**, eadh2602 (2024).
- 1061 55. Ayalew, M. *et al.* Convergent functional genomics of schizophrenia: from comprehensive
1062 understanding to genetic risk prediction. *Mol Psychiatry* **17**, 887–905 (2012).
- 1063 56. Siokas, V. *et al.* Myelin-associated oligodendrocyte basic protein rs616147 polymorphism
1064 as a risk factor for Parkinson’s disease. *Acta Neurologica Scandinavica* **145**, 223–228
1065 (2022).
- 1066 57. Arnold, S. E. *et al.* Dysregulation of olfactory receptor neuron lineage in schizophrenia.
1067 *Arch Gen Psychiatry* **58**, 829–835 (2001).
- 1068 58. Turetsky, B. I., Moberg, P. J., Arnold, S. E., Doty, R. L. & Gur, R. E. Low olfactory bulb
1069 volume in first-degree relatives of patients with schizophrenia. *Am J Psychiatry* **160**, 703–
1070 708 (2003).
- 1071 59. Almandil, N. B. *et al.* Exome-wide analysis identify multiple variations in olfactory
1072 receptor genes (OR12D2 and OR5V1) associated with autism spectrum disorder in Saudi
1073 females. *Frontiers in Medicine* **10**, (2023).
- 1074 60. Kuo, P.-H. *et al.* Genome-Wide Association Study for Autism Spectrum Disorder in
1075 Taiwanese Han Population. *PLOS ONE* **10**, e0138695 (2015).
- 1076 61. Warnica, W. *et al.* Copy number variable microRNAs in schizophrenia and their
1077 neurodevelopmental gene targets. *Biol Psychiatry* **77**, 158–166 (2015).

- 1078 62. Christen-Zaech, S. *et al.* Early Olfactory Involvement in Alzheimer’s Disease. *Canadian*
1079 *Journal of Neurological Sciences* **30**, 20–25 (2003).
- 1080 63. Murphy, C. Olfactory and other sensory impairments in Alzheimer disease. *Nat Rev Neurol*
1081 **15**, 11–24 (2019).
- 1082 64. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
1083 human phenome. *eLife* **7**, e34408 (2018).
- 1084 65. Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 1–21 (2022).
- 1085 66. 23andMe Research Team *et al.* Genome-wide association study of depression phenotypes
1086 in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun* **9**, 1470
1087 (2018).
- 1088 67. Navari, S. & Dazzan, P. Do antipsychotic drugs affect brain structure? A systematic and
1089 critical review of MRI findings. *Psychol Med* **39**, 1763–1777 (2009).
- 1090 68. Chopra, S. *et al.* Differentiating the effect of antipsychotic medication and illness on brain
1091 volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind,
1092 Placebo-controlled MRI Study. *Neuropsychopharmacol.* **46**, 1494–1501 (2021).
- 1093 69. Zeldovich, L. Cold parenting? Childhood schizophrenia? How the diagnosis of autism has
1094 evolved over time. *Science* doi: 10.1126/science.aau1206 (2018).
- 1095 70. Moreau, C. A. *et al.* Dissecting autism and schizophrenia through neuroimaging genomics.
1096 *Brain* **144**, 1943–1957 (2021).
- 1097 71. Fu, Z. *et al.* Dynamic functional network reconfiguration underlying the pathophysiology of
1098 schizophrenia and autism spectrum disorder. *Human Brain Mapping* **42**, 80–94 (2021).
- 1099 72. Berezki, E. *et al.* Synaptic markers of cognitive decline in neurodegenerative diseases: a
1100 proteomic approach. *Brain* **141**, 582–595 (2018).

- 1101 73. Jiang, C.-C. *et al.* Signalling pathways in autism spectrum disorder: mechanisms and
1102 therapeutic implications. *Sig Transduct Target Ther* **7**, 1–36 (2022).
- 1103 74. Chi, S., Yu, J.-T., Tan, M.-S. & Tan, L. Depression in Alzheimer’s disease: epidemiology,
1104 mechanisms, and management. *J Alzheimers Dis* **42**, 739–755 (2014).
- 1105 75. Dafsari, F. S. & Jessen, F. Depression—an underrecognized target for prevention of
1106 dementia in Alzheimer’s disease. *Transl Psychiatry* **10**, 1–13 (2020).
- 1107 76. Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort
1108 study. *Transl Psychiatry* **11**, 1–10 (2021).
- 1109 77. Lalousis, P. A. *et al.* Neurobiologically Based Stratification of Recent-Onset Depression
1110 and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. *Biological*
1111 *Psychiatry* **92**, 552–562 (2022).
- 1112 78. Woo, M. Eyes hint at hidden mental-health conditions. *Eyes hint at hidden mental-health*
1113 *conditions* <https://www.nature.com/articles/d41586-019-01114-9> (2019).
- 1114 79. Tahsili-Fahadan, P. & Geocadin, R. G. Heart–Brain Axis. *Circulation Research* **120**, 559–
1115 572 (2017).
- 1116 80. Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease:
1117 where do we go from here? *Nat Rev Neurol* **17**, 157–172 (2021).
- 1118 81. Murphy, C. E., Walker, A. K. & Weickert, C. S. Neuroinflammation in schizophrenia: the
1119 role of nuclear factor kappa B. *Transl Psychiatry* **11**, 1–13 (2021).
- 1120 82. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary
1121 imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 1122 83. Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome–gut–brain axis in Parkinson disease
1123 — from basic research to the clinic. *Nat Rev Neurol* **18**, 476–495 (2022).

- 1124 84. Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in
1125 behaviour and brain disorders. *Nat Rev Microbiol* **19**, 241–255 (2021).
- 1126 85. Tost, H., Champagne, F. A. & Meyer-Lindenberg, A. Environmental influence in the brain,
1127 human welfare and mental health. *Nat Neurosci* **18**, 1421–1431 (2015).
- 1128 86. UKBB, U. Ambitious project announced to create the world’s largest longitudinal imaging
1129 dataset. [https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset)
1130 [project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset).
- 1131 87. Wang, R., Chaudhari, P. & Davatzikos, C. Embracing the disharmony in medical imaging:
1132 A Simple and effective framework for domain adaptation. *Med Image Anal* **76**, 102309
1133 (2022).
- 1134 88. Tustison, N. J. *et al.* N4ITK: improved N3 bias correction. *IEEE Trans. Med. Imaging* **29**,
1135 1310–1320 (2010).
- 1136 89. Doshi, J. *et al.* MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration
1137 algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195
1138 (2016).
- 1139 90. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
1140 *Bioinformatics* **26**, 2867–2873 (2010).
- 1141 91. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
1142 stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1143 92. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-
1144 scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
- 1145 93. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
1146 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).


- 1147 94. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
1148 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1149 95. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**,
1150 580–585 (2013).
- 1151 96. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
1152 *Nat Genet* **47**, 1236–1241 (2015).
- 1153 97. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary
1154 data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).
- 1155 98. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
1156 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
1157 **44**, 512–525 (2015).
- 1158 99. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
1159 Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
- 1160 100. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer’s disease:
1161 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 1162 101. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. *Machine Learning* **52**,
1163 239–281 (2003).
- 1164

1165 **Acknowledgments**

1166 We want to express our sincere gratitude to the UK Biobank team for their invaluable
1167 contribution to advancing clinical research in our field. We thank the Psychiatric Genomics
1168 Consortium (PGC: <https://pgc.unc.edu/>) for generously sharing the GWAS summary statistics
1169 with the scientific community. This study used the UK Biobank resource under Application
1170 Numbers 35148 (CD) and 60698 (AZ). We also gratefully acknowledge the support of the
1171 iSTAGING consortium, funded by the National Institute on Aging through grant RF1 AG054409
1172 at the University of Pennsylvania (CD). Additionally, we acknowledge the funding program
1173 from the Rebecca L. Cooper Foundation at the University of Melbourne (AZ).
1174
1175


1176 **Figure caption**

1177 **Figure 1: Study workflow**



1179 **a)** The concept of semi-supervised learning methods used in this study. These AI methods model
1180 the patterns and transformations from the healthy control (CN) to the patient (PT) domain, thus
1181 capturing variations related to underlying disease pathology. Nine DNEs previously
1182 published^{1,3,2,14} from four disease-focused, case-control studies were investigated. **b)** The
1183 expression of the nine DNEs in the UK Biobank (UKBB) general population. The trained models
1184 were then applied to the UKBB population to quantify the expression of the neuroanatomical
1185 patterns of the nine DNEs at individual levels; a higher DNE score indicates a greater expression
1186 (manifestation/presence) of the respective neuroanatomical pattern. For example, the blue
1187 samples express predominantly AD2, whereas the pink samples express predominantly SCZ2.
1188 The kernel density estimate for each DNE is shown. Of note, AD1-2 DNEs are from the Surreal-
1189 GAN¹⁵ model and others from the HYDRA³¹ model, resulting in varying DNE score ranges by
1190 modeling. Overall, lower scores imply milder imaging pattern expressions. **c)** Phenome- and
1191 genome-wide analyses were performed on the nine DNEs. Phenome-wide association studies
1192 (PWAS) were conducted to associate the nine DNEs with phenotypes across nine organ systems,
1193 cognition, and lifestyle factors. Genome-wide association studies (GWAS) were performed to
1194 investigate associations between the nine DNEs and common genetic variants (SNPs). Finally,
1195 the nine DNEs and their polygenic risk scores predicted 14 disease categories (ICD-10-based), 8
1196 cognitive scores, and mortality. CN: healthy control; PT: patient.
1197
1198

1199 **Figure 2: Phenome-wide associations of the nine DNEs**




1201 **a)** The neuroanatomical patterns of the nine DNEs were manifested in the UKBB general
1202 population and were concordant with the patterns initially derived from the original disease
1203 populations^{1,3,2,14}. A linear regression model was applied to the 119 gray matter regions of
1204 interest (ROIs) derived from T1-weighted MRI data while accounting for various covariates
1205 (**Method 3b**). We present the β coefficients of the ROIs that withstood the Bonferroni
1206 correction. Positive correlations are depicted using warm reddish colors, while cold blue colors
1207 represent negative correlations. For AD2, we showed the sagittal view to visualize the
1208 hippocampus and medial temporal lobe. **b)** The nine DNEs are over-expressed (i.e., a higher
1209 mean of the DNE score in the population) and under-expressed (i.e., a lower mean of the DNE
1210 score) in the general population compared to the disease populations. The kernel density
1211 estimates of the nine DNEs are shown for both the training dataset (gray-colored in patients) and
1212 the independent test dataset from the UK Biobank (UKBB). Significant differences that survived
1213 the Bonferroni corrections between the training and independent test datasets (two-sampled t-
1214 test) are denoted with the symbol *. **c)** Phenome-wide associations (PWAS) between the nine
1215 DNEs (left panel) and 611 phenotypes (middle panel) are dominated by brain phenotypic
1216 measures. The right panel shows representative phenotypes linked to multiple phenotype
1217 categories with the highest statistical significance after the Bonferroni correction (P-
1218 value<0.05/611). A thicker colored line corresponds to a higher value of $-\log_{10}(\text{P-value})$. The
1219 symbols "+" and "-" represent positive and negative correlations. IDP: imaging-derived
1220 phenotype; OD: orientation dispersion; FA: fractional anisotropy; ICVF: intracellular volume
1221 fraction; FC: functional connectivity; DSST: digit symbol substitution test. The illustration of the
1222 human anatomy is from NIH BIOART Source (<https://bioart.niaid.nih.gov/>).
1223

1224 **Figure 3: Genome-wide associations of the nine DNEs**


1226 **a)** Genome-wide associations identified 66 (10, 8, 5, 21, 9, 1, 3, 3, 6 for the nine DNEs) genomic
1227 loci ($P\text{-value} < 5 \times 10^{-8}$) associated with the nine DNEs. Using the top lead SNP, we denoted each
1228 genomic loci linked to the 9 DNEs. Red * symbols indicate that the locus LD has not been
1229 previously associated with any trait in the EMBL-EBI GWAS catalog. The left legend indicates
1230 the significant SNP-based heritability (h^2) for the nine DNEs; the right legend represents the SNP
1231 density of our genetic data throughout the human genome. GWAS was performed using the
1232 Genome Reference Consortium Human Build 37 (GRCh37). **b)** Phenome-wide association query
1233 of the previously identified genomic loci (left panel) in the EMBL-EBI GWAS Catalog (via
1234 FUMA 1.4.2) shows a brain-dominant genetic architecture. We categorized all clinical traits
1235 (middle panel) into several high-level categories linked to multiple organ systems,
1236 neurodegenerative and neuropsychiatric disorders, lifestyle factors, etc. We then show the
1237 keyword cloud plots for each category (right panel). The illustration of the human anatomy is
1238 from NIH BIOART Source (<https://bioart.niaid.nih.gov/>).
1239

1240 **Figure 4: The genetic correlation, colocalization, and causal networks of the nine DNEs**



1242 **a)** The genetic correlation between two DNEs (g_c , lower triangle) mirrors their phenotypic
1243 correlation (p_c , upper triangle). Red-shadowed rectangles highlight two exceptions. The symbol
1244 * indicates significant results after the Benjamini-Hochberg correction. The symbol # indicates
1245 nominal significance. **b)** genetic correlations between the nine DNEs and nine biological age
1246 gaps (BAG) for nine human organ systems¹⁸. **c)** genetic correlations between the nine DNEs and
1247 six neurodegenerative and neuropsychiatric disorders. **d)** genetic correlations between the nine
1248 DNEs and four traits related to lifestyle factors and cognition. **e)** genetic colocalization was
1249 evidenced at one locus (6p21.1) between ASD2 and SCZ1. The signed PP.H4.ABF (0.92)
1250 denotes the posterior probability (PP) of hypothesis H4, which suggests that both traits share the
1251 same causal SNP (rs2790099). A positive PP indicates concordant β values for both DNEs, while
1252 a negative PP implies opposite β values. **f)** genetic colocalization was evidenced at one locus
1253 (3p.22.1) between ASD2 and brain BAG: PP.H4.ABF=0.95 with the cause SNP rs5848503. **g)**
1254 genetic colocalization was evidenced at one locus (6p.22.1) between ASD3 and SCZ case-
1255 control GWAS⁴⁶ from PGC (European ancestry): PP.H4.ABF=0.82 with the cause SNP
1256 rs9257566. **h)** the causal network of the nine DNEs with the eight multi-organ BAGs. Solid
1257 arrow lines (from the exposure to the outcome variables) indicate significant causal relationships
1258 after the Benjamini-Hochberg correction; dotted arrow lines show nominal significance (P-
1259 value<0.05). The symbols + (OR>1 and $g_c>0$) and - (OR<1 and $g_c<0$) represent a positive
1260 relationship between the two traits. **i)** the causal network of the nine DNEs with the eleven
1261 chronic diseases (e.g., AD, ADHD, BIP, and SCZ from PGC). Abbreviation: AD: Alzheimer's
1262 disease; ADHD: Attention-deficit/hyperactivity disorder; ASD: autism spectrum disorder; BIP:
1263 bipolar disorder; SCZ: schizophrenia; OCD: Obsessive-compulsive disorder; RA: rheumatoid
1264 arthritis; CD: Crohn's disease; T2D: type 2 diabetes; IBD: inflammatory bowel disease; PBC:
1265 Primary biliary cirrhosis. The illustration of the human anatomy is from NIH BIOART Source
1266 (<https://bioart.niaid.nih.gov/>).
1267

1268 **Figure 5: Additional prediction power of the nine DNEs and PRSs for 14 systemic diseases,**
1269 **cognition, and mortality outcomes**



1271 **a)** The incremental R-squared (R^2) values of the nine DNEs for predicting 14 systemic disease
1272 categories were assessed using the entire UKBB sample, with $N=39,178$ participants as
1273 independent test data. The results focusing only on the PRS target population ($N=15,891$) can be
1274 found in **Supplementary eFigure 18**. "ALL" indicates the incremental R^2 contributed by
1275 combining the nine DNEs. **b)** The incremental R^2 of the PRS of the nine DNEs to predict 14
1276 systemic diseases based on the ICD-10 code using only the PRS target sample. **c)** In the PRS
1277 target sample, disease classification accuracy from the independently hold-out test data ($N=5581$)
1278 was assessed using nested cross-validated support vector machines in the training/validation/test
1279 data ($N=10,000$) by fitting various sets of features (Cov indicates age and sex). **d)** In the PRS
1280 target sample, cognitive score prediction accuracy (Pearson's r) from the independently hold-out
1281 test data ($3632 < N < 5570$) was assessed using nested cross-validated support vector regression
1282 models. **e)** The SCZ1, SCZ1-PRS, AD1-PRS, and ASD1 show significant associations with the
1283 risk of mortality in the PRS target sample. Age and sex were included as covariates in the Cox
1284 proportional hazard model. **f)** The nine DNEs and PRSs were cumulatively included as features
1285 in cross-validation for mortality risk prediction. The symbol * indicates significant results that
1286 survived the Benjamini-Hochberg correction. The symbol # indicates nominal significance. HR:
1287 hazard ratio; CI: concordance index; DSST: digit symbol substitution test; TMT: trail-making
1288 test.